Ligustrazine, allicin and shear-induced platelet aggregation.
Liao
F
F
Jiao
L
L
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy; D001783:Blood Flow Velocity; D001792:Blood Platelets / Q000378:metabolism; D002118:Calcium / Q000097:blood; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D002560:Cerebrovascular Circulation; D004220:Disulfides; D004341:Drug Evaluation; D018056:Hemorheology; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010979:Platelet Function Tests; D011719:Pyrazines / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D013314:Stress, Mechanical; D013441:Sulfinic Acids / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D004220:Disulfides; D010975:Platelet Aggregation Inhibitors; D011719:Pyrazines; D013441:Sulfinic Acids; C006452:allicin; D002118:Calcium; C017953:tetramethylpyrazine